

(12) **UK Patent Application** (19) **GB** (11) **2 295 318** (13) **A**

(43) Date of A Publication 29.05.1996

<p>(21) Application No 9523667.5</p> <p>(22) Date of Filing 20.11.1995</p> <p>(30) Priority Data (31) 9423511 (32) 22.11.1994 (33) GB</p>	<p>(51) INT CL⁶ A61K 31/415 9/19</p> <p>(52) UK CL (Edition O) A5B BHA BLM B180 B48Y B483 B54Y B542 B55Y B551 B56Y B565 B57Y B575 B61Y B616 B62Y B626 B66Y B661 B827 B828 U1S S1318</p> <p>(56) Documents Cited EP 0226268 A2 US 5288497 A</p> <p>(58) Field of Search UK CL (Edition O) A5B BHA BJA BJB BLM INT CL⁶ A61K 9/14 9/19 31/415 ONLINE: CAS ONLINE</p>
<p>(71) Applicant(s) Glaxo Wellcome Inc (Incorporated in Canada) 7333 Mississauga Road North, Mississauga, Ontario L5N 6L4, Canada</p> <p>(72) Inventor(s) Ian Keith Winterborn</p> <p>(74) Agent and/or Address for Service Wendy Anne Filler Glaxo Wellcome Public Limited Company, Glaxo Wellcome House, Berkeley Avenue, Greenford, MIDDLESEX, UB6 0NN, United Kingdom</p>	

(54) FREEZE-DRIED COMPOSITION CONTAINING ONDANSETRON


(57) A freeze-dried composition suitable for oral administration comprises ondansetron, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, as a free base or pharmaceutically acceptable salt and one or more excipients. The composition disintegrates rapidly in the mouth and may typically be used in the treatment of diseases mediated through the actions of 5-hydroxytryptamine (5HT) and 5HT₃ receptors particularly emesis.

GB 2 295 318 A

COMPOSITIONS

The present invention relates to a pharmaceutical composition containing, as active ingredient, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-one, in particular a freeze-dried dosage form that disintegrates rapidly, for oral administration.

In UK Patent No. 2153821B we disclose, *inter alia*, 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, now known as ondansetron, which may be represented by the formula (I)



and physiologically acceptable salts, solvates and physiologically acceptable equivalents thereof.

Ondansetron is a highly selective and potent antagonist of 5-hydroxytryptamine (5HT) at 5HT₃ receptors and may be used in the treatment of a variety of conditions ameliorated by administration of 5HT₃ receptor antagonists, such as emesis (as described in European Patent Application Publication Nos. 226266 and 201165) and anxiety.

Numerous clinical studies have demonstrated the effectiveness of ondansetron for the treatment of emesis, particularly the nausea and vomiting associated with cancer chemotherapy and radiotherapy and that occurring post-operatively. Hitherto, ondansetron has always been administered in the form of a salt, in particular in the form of its hydrochloride dihydrate, either by injection or orally.

Oral administration in the form of a conventional tablet, pill or capsule constitutes the generally preferred route for administration of pharmaceuticals since this route is generally convenient and acceptable to patients. Unfortunately such compositions may be associated with certain disadvantages, particularly in the treatment of paediatric or geriatric patients, who may dislike or have difficulty in swallowing such compositions, or where administration of a conventional tablet, pill or capsule is not feasible. It is highly desirable, particularly in the treatment of acute conditions, that pharmaceutical compositions have a rapid and consistent onset of action combined with sustained activity and good bioavailability. Rapid absorption can be achieved by parenteral injection but this is unacceptable to some patients, particularly if the drug is to be administered without direct medical supervision, i.e. self-administered.

One way to overcome this problem is to administer a solid dosage form that disintegrates rapidly in the mouth, such as a freeze-dried solid dosage form, for example as described in UK Patent Nos. 1548022, 2111423, 2119246, 2114440, 2111184, 2120370, and US Patent Nos. 5046618 and 5188825, all incorporated herein by reference.

We have found that ondansetron hydrochloride dihydrate, in common with many drug substances has, however, an inherently bitter taste, and this constitutes a disadvantage for a solid dosage form that disintegrates rapidly in the mouth. Moreover, it is well known that patients may not complete a necessary course of medicine if they are prescribed an oral presentation which is particularly unpleasant to taste. To some extent the bitter taste may be masked by the use of sweetening and/or flavouring aids, although this is not entirely satisfactory, and an unpleasant after-taste may still remain in the mouth. In addition, there may be circumstances in which it is undesirable or inappropriate to use a sweetening and/or flavouring aid.

We have now found, surprisingly, that a freeze-dried dosage form that disintegrates rapidly in the mouth, comprising ondansetron in the form of its free base, provides a particularly advantageous pharmaceutical composition.

The present invention therefore provides in a first aspect a freeze-dried dosage form for oral administration capable of being rapidly disintegrated comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients.

- 5 By "rapidly disintegrated" is meant that the dosage forms are disintegrated in water within ten seconds when tested by the procedure disclosed in UK Patent No. 1548022. Preferably the dosage forms disintegrate within 5 seconds, or less.

- 10 Preferably the freeze-dried dosage forms according to the invention comprise ondansetron in the form of its free base.

- 15 It will be appreciated by those skilled in the art that ondansetron contains one chiral centre (shown by * in the formula (I)) and that ondansetron therefore exists in the form of optical isomers (i.e. enantiomers). The invention includes all isomers of ondansetron and its pharmaceutically acceptable solvates, including all tautomeric and optical forms, and mixtures thereof, including racemic mixtures.

Conveniently ondansetron, expressed as free base, may comprise 0.1 to 10% weight by weight (w/w) of the composition, such as 1 to 5% w/w, preferably 2.5 to 4% w/w, for example about 3.2% w/w.

- 20 The amount of ondansetron in the freeze-dried dosage form, expressed as free base, is conveniently in the range 0.1 to 100mg, such as 0.5 to 50mg, preferably 1 to 25mg, such as 4 or 8mg.

- 25 The freeze-dried dosage forms of the invention are, surprisingly, free of the bitter taste associated with corresponding compositions comprising ondansetron hydrochloride dihydrate.

- To be capable of being disintegrated rapidly, the freeze-dried dosage form may comprise a network of pharmaceutically acceptable water soluble or water-dispersible carrier material, conveniently as described in the patents incorporated herein by reference above, for example, in UK Patent No 1548022.
- 5 Sutable materials to act as a carrier material include, for example, gelatin (including partially hydrolysed gelatin), polysaccharides such as hydrolysed dextran, dextrin and alginates (e.g. sodium alginate) or mixtures of the above mentioned carriers with each other with other carrier materials such as polyvinyl alcohol, polyvinylpyrrolidone or acacia.
- 10 Conventional excipients which may also be employed in the freeze-dried dosage forms according to the invention include preservatives, flavouring aids, colouring aids, sweeteners, fillers, and mixtures thereof.
- 15 Sutable preservatives include one or more alkyl hydroxybenzoates or salts thereof, such as methyl, ethyl, propyl and/or butyl hydroxybenzoates; sorbic acid or a salt thereof; benzoic acid or a salt thereof; and mixtures thereof. Preferably the freeze-dried dosage forms according to the invention comprise methyl- and propyl hydroxybenzoates, as their sodium salts.
- Sutable flavouring aids include strawberry, cherry, mint and caramel flavouring aids, in particular strawberry flavouring aid.
- 20 Sutable sweeteners include, for example, sugars such as sucrose, lactose and glucose; cyclamate and salts thereof; saccharin and salts thereof; and aspartame. Preferably the sweetener of the freeze-dried dosage form of the invention is aspartame.
- 25 Sutable fillers include polyhydric alcohols, such as mannitol, sorbitol and xylitol, or mixtures thereof, which improve the physical properties of the freeze-dried dosage form. Preferably the freeze-dried dosage forms according to the invention comprise mannitol.

It will be appreciated by those skilled in the art that freeze-dried dosage forms capable of being disintegrated rapidly may be prepared by methods known in the art as, for example, described in the patents incorporated herein by reference above.

- 5 It will be further appreciated by those skilled in the art that the patents incorporated herein by reference above disclose suitable methods of packing the freeze-dried dosage forms of the invention.

10 Conveniently an aqueous composition of the components is prepared, poured into suitable moulds, frozen, and then sealed with a covering sheet adhered to the mould so as to enclose the dosage form. Preferably the dosage forms are packed in a double foil peel-back pack.

The weight of aqueous composition poured into a mould (the wet fill weight) is conveniently in the range 50 to 750mg, such as 100 to 500mg, for example 125 or 250mg.

- 15 In a further preferred aspect, the invention provides a freeze-dried dosage form for oral administration capable of being disintegrated rapidly comprising ondansetron in the form of its free base, gelatin, sodium methylhydroxybenzoate, sodium propylhydroxybenzoate, strawberry flavouring aid, aspartame, and mannitol.

- 20 In a yet further preferred aspect, the invention provides a freeze-dried dosage form wherein the wet fill weight is 125 or 250mg.

Within the above preferred aspects of the invention, a freeze-dried dosage form, wherein the amount of ondansetron is in the range 1 to 25mg, such as 4 or 8mg, is especially preferred.

- 25 In a further aspect the invention provides a method of treating a mammal, including man, suffering from a condition mediated through the action of 5HT at

5HT₃ receptors, which comprises administration of a freeze-dried dosage form for oral administration capable of being rapidly disintegrated comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms.

Conditions mediated through the action of 5HT at 5HT₃ receptors include emesis; cognitive disorders such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease and Creutzfeldt-Jakob disease), and vascular dementia (including multi-infarct dementia), as well as dementia associated with intracranial space occupying lesions, trauma, infections and related conditions (including HIV infection), metabolism, toxins, anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment; psychotic disorders, such as schizophrenia and mania; anxiety disorders, including panic disorder, agoraphobia, social phobia, simple phobia, obsessive compulsive disorders, post traumatic stress disorder, mixed anxiety and depression, and generalised anxiety disorder; irritable bowel syndrome and dependency on drugs and substances of abuse. Other conditions mediated in this manner include pruritis, particularly that induced by cholestasis; gastric stasis; symptoms of gastrointestinal dysfunction such as occur with peptic ulcer, reflux oesophagitis, flatulence and dyspepsia; migraine; obesity and conditions such as bulimia; pain; and depression.

Emesis, i.e. nausea, retching and vomiting, includes acute emesis, delayed emesis and anticipatory emesis. Ondansetron is useful in the treatment of emesis however induced. For example, emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil, cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5-fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine and vincristine; and others such as cisplatin,

dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis, or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intracranial pressure; decreased intracranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia.

The freeze-dried dosage forms according to the invention have particular utility for the treatment of emesis, particularly that associated with cancer chemotherapy and radiotherapy, but also that occurring post-operatively.

It will be appreciated that the precise therapeutic dose of the active ingredient will depend on the age and condition of the patient and the nature of the condition to be treated and will be at the ultimate discretion of the attendant physician.

However, in general, effective doses for the treatment of conditions mediated through the action of 5HT at 5HT₃ receptors, for example emesis, will lie in the range of 0.05 to 100mg, such as 0.1 to 50mg, preferably 0.5 to 25mg, for example 4, 8 or 16mg of the active ingredient per unit dose, which could be administered in single or divided doses, for example, 1 to 4 times per day.

The following non-limiting examples further illustrate the invention.

Example 1

	<u>125mg</u>	<u>250mg</u>	<u>% w/w</u>
Ondansetron Base	4.0	8.0	3.2
Gelatin Pharm Eur/USP	5.0	10.0	4.00
Mannitol Pharm Eur/USP	3.75	7.5	3.00
Aspartame USNF	0.625	1.25	0.50
Strawberry Flavouring Aid	0.125	0.25	0.1
Sodium Methylhydroxybenzoate	0.0555	0.111	0.0444
Sodium Propylhydroxybenzoate	0.0070	0.014	0.0056
Purified Water Pharm Eur/USP	qs to 125.0*	qs to 250.0*	qs to 100.0*

* The water is removed during the freeze-drying process.

5 The components of the composition are mixed together as, for example, described in the patents incorporated herein by reference above.

10 The suspension is then poured into blister moulds. For 4mg unit doses, the fill weight is 125mg; for 8mg unit doses the fill weight is 250mg. The suspension is frozen, freeze-dried, and then sealed with a covering sheet adhered to the mould, as for example described in the patents incorporated herein by reference.

Claims

1. A freeze-dried dosage form for oral administration capable of being rapidly disintegrated comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients.
5
2. A composition according to claim 1 comprising ondansetron in the form of its free base.
3. A composition according to claim 1 or 2 wherein ondansetron, expressed as free base, comprises 0.1 to 10% w/w of the composition.
- 10 4. A composition according to any one of claims 1 to 3 wherein the amount of ondansetron, expressed as free base, is in the range 0.1 to 100mg.
- 15 5. A composition according to any one of claims 1 to 4 comprising ondansetron in the form of its free base, gelatin, sodium methylhydroxybenzoate, sodium propylhydroxybenzoate, strawberry flavouring aid, aspartame, and mannitol.
6. A method of treating a mammal, including man, suffering from a condition mediated through the action of 5HT at 5HT₃ receptors, which comprises administration of a composition according to any one of claims 1 to 5.
7. A method according to claim 6 for the treatment of emesis.

10

Patents Act 1977
Examiner's report to the Comptroller under Section 17
(The Search report)

Application number
 GB 9523667.5

Relevant Technical Fields

(i) UK Cl (Ed.O) A5B (BHA, BJA, BJB, BLM)

(ii) Int Cl (Ed.6) A61K 9/14, 9/19, 31/415

Search Examiner
 DR J HOULIHAN

Date of completion of Search
 8 FEBRUARY 1996

Databases (see below)

(i) UK Patent Office collections of GB, EP, WO and US patent specifications.

(ii) ONLINE: CAS ONLINE

Documents considered relevant following a search in respect of Claims :-
 1-5

Categories of documents

- | | |
|--|---|
| <p>X: Document indicating lack of novelty or of inventive step.</p> <p>Y: Document indicating lack of inventive step if combined with one or more other documents of the same category.</p> <p>A: Document indicating technological background and/or state of the art.</p> | <p>P: Document published on or after the declared priority date but before the filing date of the present application.</p> <p>E: Patent document published on or after, but with priority date earlier than, the filing date of the present application.</p> <p>&: Member of the same patent family; corresponding document.</p> |
|--|---|

Category	Identity of document and relevant passages	Relevant to claim(s)
A	EP 0226266 A2 (GLAXO GROUP LTD) page 2, lines 1-5; page 5, lines 25-34; page 6, lines 12-13	
P, A	US 5288497 (UNI. UTAH) column 11, lines 23-43; column 13, lines 16-21; Claim 166	

Databases: The UK Patent Office database comprises classified collections of GB, EP, WO and US patent specifications as outlined periodically in the Official Journal (Patents). The on-line databases considered for search are also listed periodically in the Official Journal (Patents).